Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cd99l2 regulates excitatory synapse development and restrains immediate-early gene activation.

Cell reports·2026
Same author

Resistin signaling via NF-κB pathway plays a key role in obesity-induced and -aggravated asthma.

Life sciences·2026
Same author

Allergenic Characterization of Parvalbumin, Tric l 1, From Atlantic cutlassfish, <i>Trichiurus lepturus</i>.

Allergy, asthma & immunology research·2026
Same author

Fulminant eosinophilic myocarditis treated by venoarterial extracorporeal membrane oxygenation and adjunctive immunosuppressive therapy: a case report.

European heart journal. Case reports·2026
Same author

Automated Objective Scoring of Osteoarthritis Severity in Mouse Medial Tibial Cartilage Using Deep Learning.

Cartilage·2026
Same author

Profilin isoallergens, major but not immunodominant, from Korean melon.

The World Allergy Organization journal·2026

Related Experiment Video

Updated: Jul 20, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

9.9K

Controlled Drug Release Using Chitosan-Alginate-Gentamicin Multi-Component Beads.

Kyung Hee Park1, Yeon Woo Choi2, Heejoo Ryu1

  • 1Department of Dental Materials and Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Korea.

Materials (Basel, Switzerland)
|November 11, 2022
PubMed
Summary

Researchers developed chitosan-alginate beads for controlled antibiotic delivery. Citric acid crosslinking enabled sustained release of gentamicin, showing potential for bone restoration applications.

Keywords:
alginatebioactivitychitosancontrolled releasegentamicin

More Related Videos

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
05:26

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

3.5K
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

707

Related Experiment Videos

Last Updated: Jul 20, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

9.9K
Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
05:26

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

3.5K
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

707

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Pharmaceutical Technology

Background:

  • Bone defects and infections often require localized antibiotic delivery to enhance efficacy and minimize systemic side effects.
  • Developing effective drug delivery systems for antibiotics like gentamicin (GM) is crucial for bone restoration and infection control.
  • Chitosan and alginate are biocompatible polymers with potential for creating versatile drug delivery matrices.

Purpose of the Study:

  • To develop and characterize multi-component beads for controlled and sustained delivery of gentamicin (GM).
  • To investigate the influence of chitosan concentration and citric acid crosslinking on GM release kinetics.
  • To evaluate the suitability of these beads for bone restoration applications requiring antibiotic release.

Main Methods:

  • Preparation of single and multi-component beads via gelation using chitosan, calcium chloride, alginate, and citric acid.
  • Optimization of bead composition (sodium alginate, chitosan, citric acid concentrations) for desired release profiles.
  • Characterization of beads using FTIR, TG-DTG, swelling studies, and SEM.
  • In vitro release studies of gentamicin in phosphate buffer solution.
  • Assessment of antimicrobial activity of GM-loaded beads.

Main Results:

  • Optimized beads were formulated using 5% or 2% sodium alginate, 3% chitosan, and 0.1 mol/L citric acid.
  • Characterization confirmed the structural integrity and properties of the developed beads.
  • All gentamicin-loaded beads exhibited significant antimicrobial activity.
  • Chitosan concentration and citric acid crosslinking effectively controlled the rate and kinetics of GM release.
  • Crosslinked beads achieved approximately 80% drug release within 24 hours, demonstrating sustained-release capability.

Conclusions:

  • Chitosan-alginate beads offer a promising platform for antibiotic delivery.
  • Citric acid crosslinking is an effective strategy to achieve sustained gentamicin release from these beads.
  • The developed beads show potential for use in bone restoration, providing localized and controlled antibiotic therapy.